548 results on '"Deleuran, Mette"'
Search Results
2. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
3. Treat-to-Target in Atopic Dermatitis
4. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
5. Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council
6. Skin Barrier Abnormalities in Atopic Dermatitis
7. The doctors' perception of skin diseases in general practice in Denmark, with emphasis on atopic dermatitis: A descriptive study
8. Scabies, den store imitator
9. Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)
10. Italian S3-Guideline on the treatment of atopic eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)
11. Italian S3-Guideline on the treatment of atopic eczema Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)
12. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
13. The impact of home treatment and self-administration of omalizumab on chronic urticaria
14. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
15. Treatment and referral patterns of patients with atopic dermatitis from the Danish primary care system to the tertiary care system.
16. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.
17. Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons
18. Long-Term Efficacy Of Dupilumab In Adults With Moderate-to-Severe Atopic Dermatitis: Results From A 5-Year Open-Label Extension Trial
19. 530 - Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
20. Clinical relevance of type 2 inflammation as a driver of multi-organ disease: A Delphi consensus initiative
21. Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature
22. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
23. Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council
24. Defining and Assessing Skin Changes in Severe Acute Malnutrition (SAM)
25. Treat-to-Target in Atopic Dermatitis
26. Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo
27. Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature
28. An Emollient Containing Aquaphilus dolomiae Extract is Effective in the Management of Xerosis and Pruritus: An International, Real-World Study
29. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
30. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants
31. Current pharmaceutical developments in atopic dermatitis
32. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
33. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative
34. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
35. Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
36. ISID0551 - Atopic dermatitis in childhood and academic performance
37. Atopic eczema patients and healthcare professionals join forces in Malta
38. Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis
39. The Treat-to-Target Project in Atopic Dermatitis: One Year On
40. Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study
41. 3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis
42. Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis
43. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis
44. Short‐term real‐world experience with baricitinib treatment in Danish adults with moderate–severe atopic dermatitis
45. Inflammatory-Driven Depletion of Filaggrin Proteins
46. Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis
47. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis
48. 695 - Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis.
49. 34385 Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial
50. 33152 Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis (AD) among adults with moderate-to-severe AD treated with upadacitinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.